American officials and the pharmaceutical companies Sanofi and Astra Zeneca gathered this week at the White House to discuss vaccines against RSV for next year, with a particular focus on children and infants.
On Monday, officials and pharmaceutical companies met at the White House to address next year’s requests for immunizations against RSV, that is, respiratory syncytial virus, for children. The virus generally causes mild cold symptoms but can develop into more serious illness in infants.
“Monday’s meeting follows numerous in-person and virtual meetings to seek ways manufacturers can make more RSV immunizations available for infants”, the White House said in a statement.
The pharmaceutical companies Sanofi, and AstraZeneca’s joint RSV medicine Beyfortus, was approved earlier this year and about 77,000 doses of the vaccine have been distributed to children and infants. The number of cases is reported to have increased noticeably during the year.
Furthermore, it is announced that the Biden administration continues to prioritize vaccine production for the entire US population, focusing on infants among others.
“CDC’s Vaccines for Children program provides vaccines to half of America’s children and senior administration officials will continue to work directly with distributors and manufacturers to make sure the RSV immunization, flu vaccine, and updated COVID-19 vaccine are available to all families, with a particular focus on our most vulnerable communities, including infants”, the White House statement reads.
Related articles:
High levels of PFAS are found in juices and fruit ...
Germany is in a government crisis after Chancellor...
